☰

Charles Swanton - Publications

Affiliations: 
The Francis Crick Institute, London, England, United Kingdom 
Tree Info Grants Similar researchers PubMed Report error

325 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Dietzen M, Zhai H, Lucas O, Pich O, Barrington C, Lu WT, Ward S, Guo Y, Hynds RE, Zaccaria S, Swanton C, McGranahan N, Kanu N. Replication timing alterations are associated with mutation acquisition during breast and lung cancer evolution. Nature Communications. 15: 6039. PMID 39019871 DOI: 10.1038/s41467-024-50107-4  0.321
2024 Hobor S, Al Bakir M, Hiley CT, Skrzypski M, Frankell AM, Bakker B, Watkins TBK, Markovets A, Dry JR, Brown AP, van der Aart J, van den Bos H, Spierings D, Oukrif D, Novelli M, ... ... Swanton C, et al. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nature Communications. 15: 4871. PMID 38871738 DOI: 10.1038/s41467-024-47606-9  0.303
2024 Hill W, Weeden CE, Swanton C. Tumor Promoters and Opportunities for Molecular Cancer Prevention. Cancer Discovery. OF1-OF7. PMID 38870403 DOI: 10.1158/2159-8290.CD-24-0128  0.321
2024 Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C, Peters S. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 187: 1617-1635. PMID 38552610 DOI: 10.1016/j.cell.2024.02.041  0.343
2024 Swanton C, Bernard E, Abbosh C, André F, Auwerx J, Balmain A, Bar-Sagi D, Bernards R, Bullman S, DeGregori J, Elliott C, Erez A, Evan G, Febbraio MA, Hidalgo A, et al. Embracing cancer complexity: Hallmarks of systemic disease. Cell. 187: 1589-1616. PMID 38552609 DOI: 10.1016/j.cell.2024.02.009  0.305
2023 Usaite I, Biswas D, Dijkstra K, Watkins TB, Pich O, Puttick C, Angelova M, Thakkar K, Hiley C, Birkbak N, Kok M, Zaccaria S, Wu Y, Litchfield K, Swanton C, et al. Quantifying the impact of immunotherapy on RNA dynamics in cancer. Journal For Immunotherapy of Cancer. 11. PMID 37914385 DOI: 10.1136/jitc-2023-007870  0.313
2023 Attig J, Pape J, Doglio L, Kazachenka A, Ottina E, Young GR, Enfield KS, Aramburu IV, Ng KW, Faulkner N, Bolland W, Papayannopoulos V, Swanton C, Kassiotis G. Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin. The Journal of Clinical Investigation. PMID 37192000 DOI: 10.1172/JCI164397  0.32
2023 Weeden CE, Hill W, Lim EL, Grönroos E, Swanton C. Impact of risk factors on early cancer evolution. Cell. 186: 1541-1563. PMID 37059064 DOI: 10.1016/j.cell.2023.03.013  0.355
2023 Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, Veeriah S, Colliver E, Huebner A, Bunkum A, Hill MS, Grigoriadis K, Moore DA, Black JRM, Liu WK, ... ... Swanton C, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. PMID 37046096 DOI: 10.1038/s41586-023-05783-5  0.331
2023 Martínez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, Thol K, Jones TP, Veeriah S, Naceur-Lombardelli C, Toncheva A, Prymas P, Rowan A, Ward S, Cubitt L, ... ... Swanton C, et al. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature. PMID 37046093 DOI: 10.1038/s41586-023-05706-4  0.319
2022 Venkatesan S, Angelova M, Bartkova J, Bakhoum SF, Bartek J, Kanu N, Swanton C. APOBEC3 as a driver of genetic intratumor heterogeneity. Molecular & Cellular Oncology. 10: 2014734. PMID 38116246 DOI: 10.1080/23723556.2021.2014734  0.34
2022 Martins FC, Couturier DL, de Santiago I, Sauer CM, Vias M, Angelova M, Sanders D, Piskorz A, Hall J, Hosking K, Amirthanayagam A, Cosulich S, Carnevalli L, Davies B, Watkins TBK, ... ... Swanton C, et al. Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer. Nature Communications. 13: 6360. PMID 36289203 DOI: 10.1038/s41467-022-33870-0  0.351
2022 Lange JT, Rose JC, Chen CY, Pichugin Y, Xie L, Tang J, Hung KL, Yost KE, Shi Q, Erb ML, Rajkumar U, Wu S, Taschner-Mandl S, Bernkopf M, Swanton C, et al. The evolutionary dynamics of extrachromosomal DNA in human cancers. Nature Genetics. PMID 36123406 DOI: 10.1038/s41588-022-01177-x  0.333
2022 Pich O, Bailey C, Watkins TBK, Zaccaria S, Jamal-Hanjani M, Swanton C. The translational challenges of precision oncology. Cancer Cell. 40: 458-478. PMID 35487215 DOI: 10.1016/j.ccell.2022.04.002  0.32
2021 Vendramin R, Litchfield K, Swanton C. Cancer evolution: Darwin and beyond. The Embo Journal. 40: e108389. PMID 34459009 DOI: 10.15252/embj.2021108389  0.32
2021 Venkatesan S, Angelova M, Puttick C, Zhai H, Caswell DR, Lu WT, Dietzen M, Galanos P, Evangelou K, Bellelli R, Lim EL, Watkins TBK, Rowan A, Teixeira VH, Zhao Y, ... ... Swanton C, et al. Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. Cancer Discovery. PMID 33947663 DOI: 10.1158/2159-8290.CD-20-0725  0.348
2021 Dentro SC, Leshchiner I, Haase K, Tarabichi M, Wintersinger J, Deshwar AG, Yu K, Rubanova Y, Macintyre G, Demeulemeester J, Vázquez-García I, Kleinheinz K, Livitz DG, Malikic S, Donmez N, ... ... Swanton C, et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell. PMID 33831375 DOI: 10.1016/j.cell.2021.03.009  0.364
2021 Bailey C, Black JRM, Reading JL, Litchfield K, Turajlic S, McGranahan N, Jamal-Hanjani M, Swanton C. Tracking Cancer Evolution through the Disease Course. Cancer Discovery. 11: 916-932. PMID 33811124 DOI: 10.1158/2159-8290.CD-20-1559  0.369
2021 Cai H, Chew SK, Li C, Tsai MK, Andrejka L, Murray CW, Hughes NW, Shuldiner EG, Ashkin EL, Tang R, Hung KL, Chen LC, Lee SYC, Yousefi M, Lin WY, ... ... Swanton C, et al. A functional taxonomy of tumor suppression in oncogenic KRAS-driven lung cancer. Cancer Discovery. PMID 33608386 DOI: 10.1158/2159-8290.CD-20-1325  0.308
2021 Hynds RE, Frese KK, Pearce DR, Grönroos E, Dive C, Swanton C. Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. Open Biology. 11: 200247. PMID 33435818 DOI: 10.1098/rsob.200247  0.328
2021 Yimer HA, Tang WHW, Tummala MK, Shao S, Chung GG, Couch F, Gao J, Venn O, Kurtzman K, Swanton C, Clement JM. Detection of cancer signal for over 50 AJCC cancer types with a multi-cancer early-detection test. Journal of Clinical Oncology. 39: 3072-3072. DOI: 10.1200/JCO.2021.39.15_SUPPL.3072  0.318
2020 DeGregori J, Pharoah P, Sasieni P, Swanton C. Cancer Screening, Surrogates of Survival, and the Soma. Cancer Cell. PMID 32946774 DOI: 10.1016/J.Ccell.2020.09.003  0.344
2020 Munkhbaatar E, Dietzen M, Agrawal D, Anton M, Jesinghaus M, Boxberg M, Pfarr N, Bidola P, Uhrig S, Höckendorf U, Meinhardt AL, Wahida A, Heid I, Braren R, Mishra R, ... ... Swanton C, et al. MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nature Communications. 11: 4527. PMID 32913197 DOI: 10.1038/S41467-020-18372-1  0.417
2020 Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, ... ... Swanton C, et al. Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. PMID 32887973 DOI: 10.1038/S41586-020-2656-3  0.315
2020 Watkins TBK, Lim EL, Petkovic M, Elizalde S, Birkbak NJ, Wilson GA, Moore DA, Grönroos E, Rowan A, Dewhurst SM, Demeulemeester J, Dentro SC, Horswell S, Au L, Haase K, ... ... Swanton C, et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature. PMID 32879494 DOI: 10.1038/S41586-020-2698-6  0.365
2020 Ghorani E, Reading JL, Henry JY, de Massy MR, Rosenthal R, Turati V, Joshi K, Furness AJS, Aissa AB, Saini SK, Ramskov S, Georgiou A, Sunderland MW, Wong YNS, De Mucha MV, ... ... Swanton C, et al. The T cell differentiation landscape is shaped by tumour mutations in lung cancer. Nature Cancer. 1: 546-561. PMID 32803172 DOI: 10.1038/S43018-020-0066-Y  0.342
2020 Litchfield K, Reading JL, Lim EL, Xu H, Liu P, Al-Bakir M, Wong YNS, Rowan A, Funt SA, Merghoub T, Perkins D, Lauss M, Svane IM, Jönsson G, Herrero J, ... ... Swanton C, et al. Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature Communications. 11: 3800. PMID 32733040 DOI: 10.1038/S41467-020-17526-5  0.36
2020 Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, Garrett A, Gronthoud F, Nicol DL, Jhanji S, Boyce SA, Williams M, Riboli E, Muller DC, Kipps E, ... ... Swanton C, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. The Lancet. Oncology. PMID 32702311 DOI: 10.1016/S1470-2045(20)30392-2  0.388
2020 Pennycuick A, Teixeira VH, AbdulJabbar K, Raza SEA, Lund T, Akarca AU, Rosenthal R, Kalinke L, Chandrasekharan DP, Pipinikas CP, Lee-Six H, Hynds RE, Gowers KHC, Henry JY, Millar FR, ... ... Swanton C, et al. Immune surveillance in clinical regression of pre-invasive squamous cell lung cancer. Cancer Discovery. PMID 32690541 DOI: 10.1158/2159-8290.Cd-19-1366  0.358
2020 Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, ... ... Swanton C, et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. PMID 32669708 DOI: 10.1038/S41586-020-2481-8  0.37
2020 Bailey C, Black JRM, Swanton C. Cancer Research: The lessons to learn from COVID-19. Cancer Discovery. PMID 32669285 DOI: 10.1158/2159-8290.Cd-20-0823  0.371
2020 Rodríguez-Martínez M, Boissiére T, Gonzalez MN, Litchfield K, Mitter R, Walker J, Kjœr S, Ismail M, Downward J, Swanton C, Svejstrup JQ. Evidence That STK19 Is Not an NRAS-dependent Melanoma Driver. Cell. 181: 1395-1405.e11. PMID 32531245 DOI: 10.1016/J.Cell.2020.04.014  0.311
2020 Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, Boeing S, Krzystanek M, Djureinovic D, La Fleur L, Greco M, Döme B, Fillinger J, Brunnström H, Wu Y, ... ... Swanton C, et al. Publisher Correction: A clonal expression biomarker associates with lung cancer mortality. Nature Medicine. PMID 32494065 DOI: 10.1038/S41591-020-0899-Z  0.331
2020 Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T, Ronel T, Noursadeghi M, Turati V, Furness AJS, Georgiou A, ... ... Swanton C, et al. Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nature Medicine. PMID 32494063 DOI: 10.1038/S41591-020-0866-8  0.346
2020 Swanton C, Scowcroft H. Protecting "covid protected" cancer hubs. Bmj (Clinical Research Ed.). 369: m2062. PMID 32471824 DOI: 10.1136/Bmj.M2062  0.303
2020 AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A, Lund T, Moore DA, Salgado R, Al Bakir M, Zapata L, Hiley CT, Officer L, Sereno M, Smith CR, ... ... Swanton C, et al. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine. PMID 32461698 DOI: 10.1038/S41591-020-0900-X  0.388
2020 Swanton C. Take lessons from cancer evolution to the clinic. Nature. 581: 382-383. PMID 32461644 DOI: 10.1038/D41586-020-01347-Z  0.396
2020 Sud A, Jones M, Broggio J, Loveday C, Torr B, Garrett A, Nicol DL, Jhanji S, Boyce SA, Gronthoud F, Ward P, Handy JM, Yousaf N, Larkin J, Suh YE, ... ... Swanton C, et al. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32442581 DOI: 10.1016/J.Annonc.2020.05.009  0.37
2020 Litchfield K, Stanislaw S, Spain L, Gallegos LL, Rowan A, Schnidrig D, Rosenbaum H, Harle A, Au L, Hill SM, Tippu Z, Thomas J, Thompson L, Xu H, Horswell S, ... ... Swanton C, et al. Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports. 31: 107550. PMID 32375028 DOI: 10.1016/J.Celrep.2020.107550  0.309
2020 Loveday C, Litchfield K, Proszek PZ, Cornish AJ, Santo F, Levy M, Macintyre G, Holryod A, Broderick P, Dudakia D, Benton B, Bakir MA, Hiley C, Grist E, Swanton C, et al. Genomic landscape of platinum resistant and sensitive testicular cancers. Nature Communications. 11: 2189. PMID 32366847 DOI: 10.1038/S41467-020-15768-X  0.376
2020 Mardis ER, Ribas A, Hait WN, Jaffee EM, Foti M, Abate-Shen C, Albini A, Bernards R, Cruz-Correa MR, Flaherty KT, Greenberg PD, June CH, Knudsen KE, Liu ET, Mills GB, ... ... Swanton C, et al. AACR calls on congress to take immediate action against COVID-19 and protect patients with cancer during the pandemic Cancer Discovery. 10: 771-774. PMID 32295764 DOI: 10.1158/2159-8290.Cd-20-0449  0.376
2020 Morales Torres C, Wu MY, Hobor S, Wainwright EN, Martin MJ, Patel H, Grey W, Grönroos E, Howell S, Carvalho J, Snijders AP, Bustin M, Bonnet D, Smith PD, Swanton C, et al. Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. Nature Communications. 11: 1792. PMID 32286289 DOI: 10.1038/S41467-020-15615-Z  0.403
2020 Bailey C, Shoura MJ, Mischel PS, Swanton C. Extrachromosomal DNA - relieving heredity constraints, accelerating tumour evolution. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32275948 DOI: 10.1016/J.Annonc.2020.03.303  0.393
2020 López S, Lim EL, Horswell S, Haase K, Huebner A, Dietzen M, Mourikis TP, Watkins TBK, Rowan A, Dewhurst SM, Birkbak NJ, Wilson GA, Van Loo P, Jamal-Hanjani M, ... Swanton C, et al. Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nature Genetics. 52: 283-293. PMID 32139907 DOI: 10.1038/S41588-020-0584-7  0.478
2020 Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 31: 412-421. PMID 32067683 DOI: 10.1016/J.Annonc.2019.11.018  0.366
2020 Blagih J, Zani F, Chakravarty P, Hennequart M, Pilley S, Hobor S, Hock AK, Walton JB, Morton JP, Gronroos E, Mason S, Yang M, McNeish I, Swanton C, Blyth K, et al. Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Reports. 30: 481-496.e6. PMID 31940491 DOI: 10.1016/J.Celrep.2019.12.028  0.34
2020 Jayaram A, Goh G, Kularatne BY, Waterhouse J, Shanmugabavan Y, Rowan A, Wong YNS, Freeman A, Akarca A, Herrero J, Rosenthal R, McGranahan N, Hung M, Emberton M, Attard G, ... ... Swanton C, et al. Intratumoural (IT) evolutionary landscape of high-risk prostate cancer and outcome: The PROGENY (PROstate cancer GENomic heterogeneitY) study of genomic and immune parameters. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E17500  0.338
2020 Lindsay CR, Nicola P, Jamal-Hanjani M, Wallace A, Wilson G, Burghel G, Schlecht H, Baker K, Baker E, Priest L, Rogan J, Moghadam S, Carter M, Dive C, Bristow RG, ... Swanton C, et al. Abstract B49: “Triple wild-type” co-mutational profile in early-stage KRAS-mutant lung cancer Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-B49  0.417
2020 Cai H, Li C, Chew SK, Yousefi M, Foggetti G, Lin W, Rogers ZN, Winters IP, McFarland CD, Politi K, Swanton C, Petrov DA, Winslow MM. Abstract IA26: Multiplexed functional cancer genomics Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-Ia26  0.325
2020 Abbosh C, Frankell A, Garnett A, Harrison T, Weichert M, Licon A, Veeriah S, Daber B, Moreau M, Chesh A, Litchfield K, Lim E, Cooke D, Puttick C, Bakir MA, ... ... Swanton C, et al. Abstract CT023: Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct023  0.378
2020 Liu M, Oxnard G, Klein E, Swanton C, Seiden M, Cummings SR, Absalan F, Alexander G, Allen B, Amini H, Aravanis AM, Bagaria S, Bazargan L, Beausang JF, Berman J, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA Annals of Oncology. 31: 745-759. DOI: 10.1016/J.Annonc.2020.02.011  0.377
2019 Turajlic S, Sottoriva A, Graham T, Swanton C. Author Correction: Resolving genetic heterogeneity in cancer. Nature Reviews. Genetics. PMID 31659302 DOI: 10.1038/S41576-019-0188-1  0.333
2019 Joshi K, Robert de Massy M, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T, Ronel T, Noursadeghi M, Turati V, Furness AJS, Georgiou A, ... ... Swanton C, et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nature Medicine. PMID 31591606 DOI: 10.1038/S41591-019-0592-2  0.368
2019 Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, Boeing S, Krzystanek M, Djureinovic D, La Fleur L, Greco M, Döme B, Fillinger J, Brunnström H, Wu Y, ... ... Swanton C, et al. A clonal expression biomarker associates with lung cancer mortality. Nature Medicine. PMID 31591602 DOI: 10.1038/S41591-019-0595-Z  0.443
2019 Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, Zhou C, Wilson GA, Jamal-Hanjani M, Birkbak N, Pierce J, Kim CS, Ferdous S, Burt DJ, Slane-Tan D, ... ... Swanton C, et al. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nature Medicine. PMID 31591595 DOI: 10.1038/S41591-019-0593-1  0.378
2019 Wolf Y, Bartok O, Patkar S, Eli GB, Cohen S, Litchfield K, Levy R, Jiménez-Sánchez A, Trabish S, Lee JS, Karathia H, Barnea E, Day CP, Cinnamon E, Stein I, ... ... Swanton C, et al. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. Cell. PMID 31522890 DOI: 10.1016/J.Cell.2019.08.032  0.336
2019 McGranahan N, Swanton C. Neoantigen quality, not quantity. Science Translational Medicine. 11. PMID 31434757 DOI: 10.1126/Scitranslmed.Aax7918  0.364
2019 Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, ... ... Swanton C, et al. Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: separating biology from technical artifacts. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31349062 DOI: 10.1016/J.Jtho.2019.07.006  0.337
2019 Budczies J, Allgäuer M, Litchfield K, Rempel E, Christopoulos P, Kazdal D, Endris V, Thomas M, Fröhling S, Peters S, Swanton C, Schirmacher P, Stenzinger A. Optimizing panel-based tumor mutational burden (TMB) measurement. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31268125 DOI: 10.1093/Annonc/Mdz205  0.305
2019 Turajlic S, Sottoriva A, Graham T, Swanton C. Resolving genetic heterogeneity in cancer. Nature Reviews. Genetics. PMID 30918367 DOI: 10.1038/S41576-019-0114-6  0.459
2019 Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Cǎlin AM, Pizzi AD, Lalezari F, Lambregts DMJ, Rohaan MW, Parmar C, Rozeman EA, Hartemink KJ, Swanton C, Haanen JBAG, Blank CU, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers Annals of Oncology. 30: 998-1004. PMID 30895304 DOI: 10.1093/Annonc/Mdz108  0.368
2019 Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, Joshi K, Henry JY, Ghorani E, Wilson GA, Birkbak NJ, Jamal-Hanjani M, ... ... Swanton C, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. PMID 30894752 DOI: 10.1038/S41586-019-1032-7  0.378
2019 Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. The Lancet. Oncology. PMID 30857956 DOI: 10.1016/S1470-2045(18)30904-5  0.424
2019 Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, Mak RH, Tamimi RM, Tempany CM, Swanton C, Hoffmann U, et al. Artificial intelligence in cancer imaging: Clinical challenges and applications. Ca: a Cancer Journal For Clinicians. PMID 30720861 DOI: 10.3322/Caac.21552  0.406
2019 Teixeira VH, Pipinikas CP, Pennycuick A, Lee-Six H, Chandrasekharan D, Beane J, Morris TJ, Karpathakis A, Feber A, Breeze CE, Ntolios P, Hynds RE, Falzon M, Capitanio A, Carroll B, ... ... Swanton C, et al. Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nature Medicine. PMID 30664780 DOI: 10.1038/S41591-018-0323-0  0.455
2019 Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, ... ... Swanton C, et al. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30624547 DOI: 10.1093/Annonc/Mdy553  0.359
2019 Uddin I, Joshi K, Oakes T, Heather JM, Swanton C, Chain B. An Economical, Quantitative, and Robust Protocol for High-Throughput T Cell Receptor Sequencing from Tumor or Blood. Methods in Molecular Biology (Clifton, N.J.). 1884: 15-42. PMID 30465193 DOI: 10.1007/978-1-4939-8885-3_2  0.327
2019 Budczies J, Allgäuer M, Litchfield K, Rempel E, Christopoulos P, Kazdal D, Endris V, Thomas M, Fröhling S, Peters S, Swanton C, Schirmacher P, Stenzinger A. Evaluation of TMB estimates for the prediction of response to immune checkpoint blockage. Journal of Clinical Oncology. 37: 2632-2632. DOI: 10.1200/Jco.2019.37.15_Suppl.2632  0.31
2019 Ghorani E, Reading JL, Henry JY, Massy MRD, Rosenthal R, Furness AJS, Aissa AB, Jamal-Hanjani M, Birkbak N, Wilson G, Salgado R, Lund T, Hiley CT, Loi S, Hackshaw A, ... ... Swanton C, et al. Association of the imbalance between early and late differentiated intra-tumor CD4 T cells with mutational burden in non-small cell lung cancer. Journal of Clinical Oncology. 37: 2590-2590. DOI: 10.1200/Jco.2019.37.15_Suppl.2590  0.309
2019 Lu W, Zalmas L, Webber T, Kanu N, Swanton C. Abstract 2567: TRACERx: Intra-tumor subclonal driver mutation results in defective DNA damage response (DDR) and genome instability Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2567  0.313
2019 Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, Krzystanek M, Djureinovic D, Wu Y, Moore DA, Skrypski M, Abbosh C, Bakir MA, Watkins TB, Veeriah S, ... ... Swanton C, et al. Abstract 2678: A clonal expression biomarker improves prognostic accuracy: TRACERx lung Cancer Research. 79: 2678-2678. DOI: 10.1158/1538-7445.Am2019-2678  0.413
2019 Watts C, Apps J, Ansorg O, Savage J, Fox R, Chalmers A, Short SC, Thompson G, Waldman A, Capper D, Hargrave D, Brennan P, Smith S, Ashkan K, Wykes V, ... ... Swanton C, et al. RBTT-06. TESSA JOWELL BRAIN MATRIX STUDY: A BRITISH FEASIBILITY STUDY OF MOLECULAR STRATIFICATION AND TARGETED THERAPY TO OPTIMIZE THE CLINICAL MANAGEMENT OF PATIENTS WITH GLIOMA Neuro-Oncology. 21: vi219-vi220. DOI: 10.1093/Neuonc/Noz175.918  0.349
2019 Litchfield K, Swanton C, Turajlic S, McGranahan N, Quezada S. Contrasting the drivers of response to immunotherapy across solid tumour types: Results from analysis of > 1000 cases Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz413.012  0.335
2019 Biswas D, Birkbak NJ, McGranahan N, Swanton C. Using single cell data to validate the cellular origins of a clonal expression biomarker in lung cancer Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz413.010  0.39
2019 Au L, Litchfield K, Rowan A, Horswell S, Byrne F, Nicol D, Fotiadis N, Salgado RF, Hazell S, Lopez JI, Hatipoglu E, Rosario LD, Pickering L, Gore M, Chain B, ... ... Swanton C, et al. ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz249.006  0.342
2019 Middleton G, Popat S, Fletcher P, Summers YJ, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Savage J, Sharpe R, Yap T, Swanton C, et al. PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.060  0.327
2018 Winter H, Faull I, Bains P, Murias C, Kushnir M, Forster MD, Kulkarni A, Moore D, Swanton C, Shiu K, Arkenau HT. Circulating tumour DNA experience in patients with cancer of unknown primary. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii48. PMID 32137234 DOI: 10.1093/Annonc/Mdy269.150  0.362
2018 Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S. Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30395155 DOI: 10.1093/Annonc/Mdy495  0.325
2018 Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, Georgiou A, Furness AJS, Ben Aissa A, Ghorani E, Oakes T, Uddin I, Tan WS, Feber A, McGovern U, ... Swanton C, et al. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. The Journal of Experimental Medicine. PMID 30257862 DOI: 10.1084/Jem.20181003  0.386
2018 Turajlic S, Swanton C, Boshoff C. Kidney cancer: The next decade. The Journal of Experimental Medicine. 215: 2477-2479. PMID 30217855 DOI: 10.1084/Jem.20181617  0.36
2018 Mackay HL, Moore D, Hall C, Birkbak NJ, Jamal-Hanjani M, Karim SA, Phatak VM, Piñon L, Morton JP, Swanton C, Le Quesne J, Muller PAJ. Publisher Correction: Genomic instability in mutant p53 cancer cells upon entotic engulfment. Nature Communications. 9: 3540. PMID 30154405 DOI: 10.1038/S41467-018-06026-2  0.379
2018 Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30137196 DOI: 10.1093/Annonc/Mdy263  0.377
2018 Hiom SC, Kumar HS, Swanton C, Baldwin DR, Peake MD. Lung cancer in the UK: addressing geographical inequality and late diagnosis. The Lancet. Oncology. 19: 1015-1017. PMID 30102211 DOI: 10.1016/S1470-2045(18)30496-0  0.362
2018 Mackay HL, Moore D, Hall C, Birkbak NJ, Jamal-Hanjani M, Karim SA, Phatak VM, Piñon L, Morton JP, Swanton C, Le Quesne J, Muller PAJ. Genomic instability in mutant p53 cancer cells upon entotic engulfment. Nature Communications. 9: 3070. PMID 30076358 DOI: 10.1038/S41467-018-05368-1  0.334
2018 Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nature Reviews. Clinical Oncology. 15: 577-586. PMID 29968853 DOI: 10.1038/S41571-018-0058-3  0.375
2018 Reading JL, Gálvez-Cancino F, Swanton C, Lladser A, Peggs KS, Quezada SA. The function and dysfunction of memory CD8 T cells in tumor immunity. Immunological Reviews. 283: 194-212. PMID 29664561 DOI: 10.1111/Imr.12657  0.315
2018 Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, ... ... Swanton C, et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. PMID 29657128 DOI: 10.1016/J.Ccell.2018.03.018  0.387
2018 Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, Nicol D, O'Brien T, Larkin J, Horswell S, Stares M, Au L, Jamal-Hanjani M, Challacombe B, Chandra A, ... ... Swanton C, et al. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell. PMID 29656895 DOI: 10.1016/J.Cell.2018.03.057  0.382
2018 Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, O'Brien T, Lopez JI, Watkins TBK, Nicol D, Stares M, Challacombe B, Hazell S, Chandra A, Mitchell TJ, ... ... Swanton C, et al. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell. PMID 29656894 DOI: 10.1016/J.Cell.2018.03.043  0.356
2018 Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, Martincorena I, Tarpey P, Angelopoulos N, Yates LR, Butler AP, Raine K, Stewart GD, Challacombe B, Fernando A, ... ... Swanton C, et al. Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. Cell. PMID 29656891 DOI: 10.1016/J.Cell.2018.02.020  0.398
2018 Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, ... ... Swanton C, et al. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell. PMID 29576375 DOI: 10.1016/J.Ccell.2018.02.010  0.304
2018 Hynds RE, Ben Aissa A, Gowers KHC, Watkins TBK, Bosshard-Carter L, Rowan AJ, Veeriah S, Wilson GA, Quezada SA, Swanton C, Janes SM. Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors. International Journal of Cancer. PMID 29569246 DOI: 10.1002/Ijc.31383  0.434
2018 Ghorani E, Rosenthal R, McGranahan N, Reading JL, Lynch M, Peggs KS, Swanton C, Quezada SA. Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: 271-279. PMID 29361136 DOI: 10.1093/Annonc/Mdx687  0.352
2018 Abbosh C, Swanton C, Birkbak NJ. Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer. Annals of Oncology. 29: 535-537. PMID 29351578 DOI: 10.1093/Annonc/Mdy017  0.379
2018 Bakhoum SF, Ngo B, Laughney AM, Cavallo JA, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK, Duran M, Pauli C, Shaw C, Chadalavada K, Rajasekhar VK, ... ... Swanton C, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. PMID 29342134 DOI: 10.1038/Nature25432  0.352
2018 Swanton C. Cancer therapeutics through an evolutionary lens. Journal of the Royal Society of Medicine. 111: 8-14. PMID 29338594 DOI: 10.1177/0141076817742096  0.418
2018 Venkatesan S, Rosenthal R, Kanu N, McGranahan N, Bartek J, Quezada SA, Hare J, Harris RS, Swanton C. APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29324969 DOI: 10.1093/Annonc/Mdy003  0.389
2018 Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017753780. PMID 29320312 DOI: 10.1200/Jco.2017.75.3780  0.372
2018 Sansregret L, Vanhaesebroeck B, Swanton C. Determinants and clinical implications of chromosomal instability in cancer. Nature Reviews. Clinical Oncology. 15: 139-150. PMID 29297505 DOI: 10.1038/Nrclinonc.2017.198  0.479
2018 Oxnard GR, Maddala T, Hubbell E, Aravanis A, Zhang N, Venn O, Valouev A, Shen L, Patel S, Jamshidi A, Jagadeesh K, Gross S, Filippova D, Beausang JF, Liu MC, ... ... Swanton C, et al. Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study. Journal of Clinical Oncology. 36: LBA8501-LBA8501. DOI: 10.1200/Jco.2018.36.18_Suppl.Lba8501  0.417
2018 Joshi K, Ismail M, Reading JL, Massy MRD, Uddin I, Jamal-Hanjani M, Veeriah S, Oakes T, Wong YNS, Furness AJS, Ghorani E, Georgiou A, Beastall C, Mangal N, Aissa AB, ... ... Swanton C, et al. Characterisation of the TCR repertoire in NSCLC to reveal the relationship between TCR heterogeneity and genetic heterogeneity that is influenced by mutational load and is associated with disease recurrence. Journal of Clinical Oncology. 36: 12009-12009. DOI: 10.1200/Jco.2018.36.15_Suppl.12009  0.386
2018 Swanton C, Venn O, Aravanis A, Hubbell E, Maddala T, Beausang JF, Filippova D, Gross S, Jamshidi A, Shen L, Valouev A, Zhang N, Bolton KL, Yeatman TJ, Seiden M, et al. Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study. Journal of Clinical Oncology. 36: 12003-12003. DOI: 10.1200/Jco.2018.36.15_Suppl.12003  0.336
2018 Bakhoum SF, Ngo B, Bakhoum AL, Cavallo J, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBk, Taunk NK, Duran M, Pauli C, Shaw C, Chadalavada K, Rajasekhar VK, ... ... Swanton C, et al. Abstract NG03: Chromosomal instability promotes metastasis through a cytosolic DNA response Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ng03  0.417
2018 Aravanis AA, Oxnard GR, Maddala T, Hubbell E, Venn O, Jamshidi A, Shen L, Amini H, Beausang JA, Betts C, Civello D, Davydov K, Fazullina S, Filippova D, Gnerre S, ... ... Swanton C, et al. Abstract LB-343: Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA) Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-343  0.427
2018 Chemi F, Gulati S, Rothwell DG, Burt D, Slan-Tan D, Mesquita B, Wirth C, Wilson G, Pierce J, Brady G, Swanton C, Dive C. Abstract 5601: Single-cell molecular profiling of circulating tumor cells (CTCs) within the TRACERx study reveals heterogeneous patterns in early non-small cell lung cancer (NSCLC) Cancer Research. 78: 5601-5601. DOI: 10.1158/1538-7445.Am2018-5601  0.419
2018 McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Loo PV, Herrero J, Swanton C. Abstract LB-A03: Allele specific HLA loss and immune escape in lung cancer evolution Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-A03  0.398
2018 Jamal-Hanjani M, Huebner A, McGranahan N, Swanton C. Defining the lethal subclone in metastatic lung cancer. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy424  0.381
2018 Kushnir M, Winter H, Murias C, Bains P, Abbosh CZ, Papadatos-Pastos D, Newsome-Davis T, Ahmed T, Swanton C, Forster MD, Moore D, Bennett P, Faull I, Lanman RB, Arkenau H-. Cell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy292.052  0.369
2017 Abbosh C, Venkatesan S, Janes SM, Fitzgerald RC, Swanton C. Evolutionary dynamics in pre-invasive neoplasia. Current Opinion in Systems Biology. 2: 1-8. PMID 30603736 DOI: 10.1016/J.Coisb.2017.02.009  0.33
2017 Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, ... ... Swanton C, et al. Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. PMID 29258292 DOI: 10.1038/Nature25161  0.338
2017 Berenjeno IM, Piñeiro R, Castillo SD, Pearce W, McGranahan N, Dewhurst SM, Meniel V, Birkbak NJ, Lau E, Sansregret L, Morelli D, Kanu N, Srinivas S, Graupera M, Parker VER, ... ... Swanton C, et al. Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. Nature Communications. 8: 1773. PMID 29170395 DOI: 10.1038/S41467-017-02002-4  0.418
2017 McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. PMID 29107330 DOI: 10.1016/J.Cell.2017.10.001  0.346
2017 Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, ... ... Swanton C, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics. PMID 29106415 DOI: 10.1038/Ng.3990  0.436
2017 Linch M, Goh G, Hiley C, Shanmugabavan Y, McGranahan N, Rowan A, Wong YNS, King H, Furness A, Freeman A, Linares J, Akarca A, Herrero J, Rosenthal R, Harder N, ... ... Swanton C, et al. Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: 2472-2480. PMID 28961847 DOI: 10.1093/Annonc/Mdx355  0.326
2017 Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, Anderson KS, Gatenby R, Swanton C, Posada D, Wu CI, et al. Classifying the evolutionary and ecological features of neoplasms. Nature Reviews. Cancer. PMID 28912577 DOI: 10.1038/Nrc.2017.69  0.395
2017 McGranahan N, Swanton C. Cancer Evolution Constrained by the Immune Microenvironment. Cell. 170: 825-827. PMID 28841415 DOI: 10.1016/J.Cell.2017.08.012  0.391
2017 Sahai E, Swanton C. Evolution and cancer medicine - transformative insights. Nature Reviews. Clinical Oncology. 14: 709-710. PMID 28829058 DOI: 10.1038/Nrclinonc.2017.121  0.432
2017 Litchfield K, Turajlic S, Swanton C. The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset Released. Cancer Discovery. 7: 796-798. PMID 28765114 DOI: 10.1158/2159-8290.Cd-17-0604  0.348
2017 Amirouchene-Angelozzi N, Swanton C, Bardelli A. Tumor Evolution as a Therapeutic Target. Cancer Discovery. PMID 28729406 DOI: 10.1158/2159-8290.Cd-17-0343  0.398
2017 Turajlic S, Swanton C. TRACERx Renal: tracking renal cancer evolution through therapy Nature Reviews Urology. 14. PMID 28720862 DOI: 10.1038/Nrurol.2017.112  0.33
2017 Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M, Chambers T, Salgado R, Savas P, Loi S, Birkbak NJ, ... ... Swanton C, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. The Lancet. Oncology. PMID 28694034 DOI: 10.1016/S1470-2045(17)30516-8  0.35
2017 Naxerova K, Reiter JG, Brachtel E, Lennerz JK, van de Wetering M, Rowan A, Cai T, Clevers H, Swanton C, Nowak MA, Elledge SJ, Jain RK. Origins of lymphatic and distant metastases in human colorectal cancer. Science (New York, N.Y.). 357: 55-60. PMID 28684519 DOI: 10.1126/Science.Aai8515  0.352
2017 Wong YNS, Joshi K, Pule M, Peggs KS, Swanton C, Quezada SA, Linch M. Evolving adoptive cellular therapies in urological malignancies. The Lancet. Oncology. 18: e341-e353. PMID 28593860 DOI: 10.1016/S1470-2045(17)30327-3  0.4
2017 Turajlic S, Swanton C. Implications of cancer evolution for drug development. Nature Reviews. Drug Discovery. 16: 441-442. PMID 28450743 DOI: 10.1038/Nrd.2017.78  0.349
2017 Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Quesne JL, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, ... ... Swanton C, et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature. PMID 28445469 DOI: 10.1038/Nature22364  0.438
2017 Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, ... ... Swanton C, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. The New England Journal of Medicine. PMID 28445112 DOI: 10.1056/Nejmoa1616288  0.476
2017 Savas P, Teo ZL, Lefevre C, Flensburg C, Caramia F, Alsop K, Mansour M, Francis PA, Thorne HA, Silva MJ, Kanu N, Dietzen M, Rowan A, Kschischo M, Fox S, ... ... Swanton C, et al. Correction: The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". Plos Medicine. 14: e1002302. PMID 28430777 DOI: 10.1371/Journal.Pmed.1002302  0.313
2017 Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, ... ... Swanton C, et al. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity. PMID 28410988 DOI: 10.1016/J.Immuni.2017.03.013  0.302
2017 Qazi MA, Vora P, Venugopal C, Sidhu SS, Moffat J, Swanton C, Singh SK. Intratumoral Heterogeneity: Pathways to Treatment Resistance and Relapse in Human Glioblastoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28407030 DOI: 10.1093/Annonc/Mdx169  0.364
2017 Morrissy AS, Cavalli FM, Remke M, Ramaswamy V, Shih DJ, Holgado BL, Farooq H, Donovan LK, Garzia L, Agnihotri S, Kiehna EN, Mercier E, Mayoh C, Papillon-Cavanagh S, Nikbakht H, ... ... Swanton C, et al. Spatial heterogeneity in medulloblastoma. Nature Genetics. PMID 28394352 DOI: 10.1038/Ng.3838  0.342
2017 Venkatesan S, Swanton C, Taylor BS, Costello JF. Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. Cold Spring Harbor Perspectives in Medicine. PMID 28289245 DOI: 10.1101/Cshperspect.A026617  0.387
2017 Venkatesan S, Birkbak NJ, Swanton C. Constraints in cancer evolution. Biochemical Society Transactions. 45: 1-13. PMID 28202655 DOI: 10.1042/Bst20160229  0.451
2017 McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 168: 613-628. PMID 28187284 DOI: 10.1016/J.Cell.2017.01.018  0.385
2017 Crockford A, Zalmas LP, Grönroos E, Dewhurst SM, McGranahan N, Cuomo ME, Encheva V, Snijders AP, Begum J, Purewal S, Cerveira J, Patel H, Renshaw MJ, Swanton C. Cyclin D mediates tolerance of genome-doubling in cancers with functional p53. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: 149-156. PMID 28177473 DOI: 10.1093/Annonc/Mdw612  0.332
2017 López-García C, Sansregret L, Domingo E, McGranahan N, Hobor S, Birkbak NJ, Horswell S, Grönroos E, Favero F, Rowan AJ, Matthews N, Begum S, Phillimore B, Burrell R, Oukrif D, ... ... Swanton C, et al. BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer. Cancer Cell. 31: 79-93. PMID 28073006 DOI: 10.1016/J.Ccell.2016.11.001  0.456
2017 Sansregret L, Patterson JO, Dewhurst S, López-García C, Koch A, McGranahan N, Chao WC, Barry DJ, Rowan A, Instrell R, Horswell S, Way M, Howell M, Singleton MR, Medema RH, ... ... Swanton C, et al. APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability. Cancer Discovery. PMID 28069571 DOI: 10.1158/2159-8290.Cd-16-0645  0.464
2017 Sansregret L, Swanton C. The Role of Aneuploidy in Cancer Evolution Cold Spring Harbor Perspectives in Medicine. 7. PMID 28049655 DOI: 10.1101/Cshperspect.A028373  0.455
2017 Bryce AH, Kurzrock R, Meric-Bernstam F, Hurwitz H, Hainsworth JD, Spigel DR, Bose R, Swanton C, Burris HA, Guo S, Yoo B, Beattie MS, Tayama D, Sweeney C. Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway. Journal of Clinical Oncology. 35: 348-348. DOI: 10.1200/Jco.2017.35.6_Suppl.348  0.332
2017 Hurwitz H, Raghav KPS, Burris HA, Kurzrock R, Sweeney C, Meric-Bernstam F, Vanderwalde AM, Spigel DR, Bose R, Fakih M, Swanton C, Guo S, Bernaards C, Beattie MS, Sommer N, et al. Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. Journal of Clinical Oncology. 35: 676-676. DOI: 10.1200/Jco.2017.35.4_Suppl.676  0.386
2017 Javle MM, Hainsworth JD, Swanton C, Burris HA, Kurzrock R, Sweeney C, Meric-Bernstam F, Spigel DR, Bose R, Guo S, Bernaards C, Beattie MS, Scappaticci FA, Hurwitz H. Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway. Journal of Clinical Oncology. 35: 402-402. DOI: 10.1200/Jco.2017.35.4_Suppl.402  0.452
2017 Hiley CT, Ahmad T, Jamal-Hanjani M, Abbosh C, Ngai Y, Hackshaw A, Patterson P, Baijal S, Nicolson M, Lester JF, Krebs M, Ottensmeier CHH, Fennell DA, Schmid P, Ezhil M, ... ... Swanton C, et al. Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II). Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps9099  0.415
2017 Hainsworth JD, Bose R, Sweeney C, Meric-Bernstam F, Hurwitz H, Swanton C, Burris HA, Kurzrock R, Yoo B, Beattie MS, Gupta R, Patel RD, Schulze K, Spigel DR. Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway. Journal of Clinical Oncology. 35: 9073-9073. DOI: 10.1200/Jco.2017.35.15_Suppl.9073  0.357
2017 Kurzrock R, Meric-Bernstam F, Hurwitz H, Hainsworth JD, Spigel DR, Bose R, Swanton C, Burris HA, Sweeney C, Yoo B, Beattie MS, Patel R, Schulze K, Lam ET. Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway. Journal of Clinical Oncology. 35: 6086-6086. DOI: 10.1200/Jco.2017.35.15_Suppl.6086  0.442
2017 Wong YNS, Joshi K, Khetrapal P, Ismail M, Linares J, Akarca AU, Reading JL, Furness A, Feber A, McGovern U, Swanton C, Freeman A, Briggs TP, Kelly J, Marafioti T, et al. 879PUrine-derived lymphocytes (UDLs) as a non-invasive surrogate marker of tumour infiltrating lymphocytes (TILs) in patients with muscle invasive bladder cancer (MIBC) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx371.033  0.343
2017 Uccello M, Kushnir M, Mak G, Henriquez CM, Abbosh C, Papadatos-Pastos D, Newsom-Davis T, Ahmad T, Swanton C, Forster M, Lanman R, Faull I, Arkenau H. 134PCirculating tumour DNA (ctDNA) in the clinical management of patients (pts) with advanced non-small cell lung cancer (NSCLC): A single centre experience Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx363.050  0.368
2016 Burrell RA, Swanton C. Re-Evaluating Clonal Dominance in Cancer Evolution. Trends in Cancer. 2: 263-276. PMID 28741512 DOI: 10.1016/J.Trecan.2016.04.002  0.416
2016 Savas P, Teo ZL, Lefevre C, Flensburg C, Caramia F, Alsop K, Mansour M, Francis PA, Thorne HA, Silva MJ, Kanu N, Dietzen M, Rowan A, Kschischo M, Fox S, ... ... Swanton C, et al. The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". Plos Medicine. 13: e1002204. PMID 28027312 DOI: 10.1371/journal.pmed.1002204  0.312
2016 Goh G, Schmid R, Guiver K, Arpornwirat W, Chitapanarux I, Ganju V, Im SA, Kim SB, Dechaphunkul A, Maneechavakajorn J, Spector N, Yau T, Afrit M, Ahmed SB, Johnston SR, ... ... Swanton C, et al. Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. Plos Medicine. 13: e1002136. PMID 27923043 DOI: 10.1371/Journal.Pmed.1002136  0.37
2016 Kanu N, Cerone MA, Goh G, Zalmas LP, Bartkova J, Dietzen M, McGranahan N, Rogers R, Law EK, Gromova I, Kschischo M, Walton MI, Rossanese OW, Bartek J, Harris RS, ... ... Swanton C, et al. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biology. 17: 185. PMID 27634334 DOI: 10.1186/S13059-016-1042-9  0.406
2016 Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G, Swanton C. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet (London, England). 388: 1002-11. PMID 27598680 DOI: 10.1016/S0140-6736(16)31340-X  0.407
2016 Bentzen AK, Marquard AM, Lyngaa R, Saini SK, Ramskov S, Donia M, Such L, Furness AJ, McGranahan N, Rosenthal R, Straten PT, Szallasi Z, Svane IM, Swanton C, Quezada SA, et al. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nature Biotechnology. PMID 27571370 DOI: 10.1038/Nbt.3662  0.306
2016 Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European Urology. PMID 27567210 DOI: 10.1016/J.Eururo.2016.08.024  0.349
2016 Zámborszky J, Szikriszt B, Gervai JZ, Pipek O, Póti Á, Krzystanek M, Ribli D, Szalai-Gindl JM, Csabai I, Szallasi Z, Swanton C, Richardson AL, Szüts D. Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene. PMID 27452521 DOI: 10.1038/Onc.2016.243  0.349
2016 Venkatesan S, Swanton C. Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 35: e141-9. PMID 27249716 DOI: 10.1200/EDBK_158930  0.341
2016 Swanton C, Govindan R. Clinical implications of genomic discoveries in lung cancer New England Journal of Medicine. 374: 1864-1873. PMID 27168435 DOI: 10.1056/Nejmra1504688  0.394
2016 Szikriszt B, Póti Á, Pipek O, Krzystanek M, Kanu N, Molnár J, Ribli D, Szeltner Z, Tusnády GE, Csabai I, Szallasi Z, Swanton C, Szüts D. A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biology. 17: 99. PMID 27161042 DOI: 10.1186/S13059-016-0963-7  0.421
2016 Swanton C, Soria JC, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, de Koning L, Dive C, Feunteun J, Leung SY, Marais R, Mardis ER, McGranahan N, Middleton G, Quezada SA, et al. Consensus on precision medicine for metastatic cancers: A report from the MAP conference. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27143638 DOI: 10.1093/Annonc/Mdw192  0.406
2016 Scelo G, Hofmann JN, Banks RE, Bigot P, Bhatt RS, Cancel-Tassin G, Chew SK, Creighton CJ, Cussenot O, Davis IJ, Escudier B, Frayling TM, Häggström C, Hildebrandt MA, Holcatova I, ... ... Swanton C, et al. International cancer seminars - A focus on kidney cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27130845 DOI: 10.1093/Annonc/Mdw186  0.419
2016 Turajlic S, Swanton C. Metastasis as an evolutionary process Science. 352: 169-175. PMID 27124450 DOI: 10.1126/Science.Aaf2784  0.359
2016 McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, ... ... Swanton C, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, N.Y.). PMID 26940869 DOI: 10.1126/Science.Aaf1490  0.387
2016 Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biology. 17: 31. PMID 26899170 DOI: 10.1186/S13059-016-0893-4  0.352
2016 Hiley CT, Swanton C. Pruning Cancer's Evolutionary Tree with Lesion-Directed Therapy Cancer Discovery. 6: 122-124. PMID 26851181 DOI: 10.1158/2159-8290.Cd-15-1493  0.407
2016 Jamal-Hanjani M, Wilson GA, Horswell S, Mitter R, Sakarya O, Constantin T, Salari R, Kirkizlar E, Sigurjonsson S, Pelham R, Kareht S, Zimmermann B, Swanton C. Detection of Ubiquitous and Heterogeneous Mutations in Cell-Free DNA from Patients with Early-Stage Non-Small-Cell Lung Cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26823523 DOI: 10.1093/Annonc/Mdw037  0.381
2016 Hurwitz H, Hainsworth JD, Swanton C, Perez EA, Sweeney C, Burris HA, Spigel D, Meric-Bernstam F, Strickland DK, Leon L, Brammer M, Beattie MS, Bose R. Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors. Journal of Clinical Oncology. 34: 653-653. DOI: 10.1200/Jco.2016.34.4_Suppl.653  0.354
2016 Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris HA, Bose R, Guo S, Bernaards C, Beattie MS, Stein A, Brammer M, Kurzrock R. Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study. Journal of Clinical Oncology. 34: LBA11511-LBA11511. DOI: 10.1200/Jco.2016.34.18_Suppl.Lba11511  0.349
2016 Lopez-Garcia C, McGranahan N, Hobor S, Birkbak N, Domingo E, Rowan A, Tomlinson I, Swanton C. Abstract 3584: Genomic analysis reveals a role for BCL9L in aneuploidy tolerance in colorectal cancer Cancer Research. 76: 3584-3584. DOI: 10.1158/1538-7445.Am2016-3584  0.458
2016 Miller R, Brown N, Speirs A, Shaw H, Adeleke S, Gougis P, Bennett P, Meyer T, Swanton C, Forster, Kristeleit R. The use of next generation sequencing (NGS) to guide patient selection for phase 1 clinical trials Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw368.44  0.353
2016 Gulati S, Rothwell DG, Burt D, Mesquita B, Wirth C, Wilson G, Pierce J, Brady G, Swanton C, Dive C. Molecular profiling of circulating tumour cells (CTCs) in non-small cell lung cancer within the TRACERx study of intratumoural heterogeneity and evolution European Journal of Cancer. 61. DOI: 10.1016/S0959-8049(16)61658-1  0.39
2015 Bruin ECd, McGranahan N, Swanton C. Analysis of intratumor heterogeneity unravels lung cancer evolution. Molecular and Cellular Oncology. 2. PMID 27308463 DOI: 10.4161/23723556.2014.985549  0.396
2015 Turajlic S, Larkin J, Swanton C. SnapShot: Renal Cell Carcinoma. Cell. 163: 1556-1556.e1. PMID 26638079 DOI: 10.1016/J.Cell.2015.11.026  0.301
2015 Dewhurst S, Swanton C. Tetraploidy and CIN: a dangerous combination. Cell Cycle (Georgetown, Tex.). 14: 3217. PMID 26517196 DOI: 10.1080/15384101.2015.1084208  0.451
2015 Marquard AM, Birkbak NJ, Thomas CE, Favero F, Krzystanek M, Lefebvre C, Ferté C, Jamal-Hanjani M, Wilson GA, Shafi S, Swanton C, André F, Szallasi Z, Eklund AC. TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen. Bmc Medical Genomics. 8: 58. PMID 26429708 DOI: 10.1186/S12920-015-0130-0  0.384
2015 Birkbak NJ, Hiley CT, Swanton C. Evolutionary Precision Medicine: A Role for Repeat Epidermal Growth Factor Receptor Analysis in ALK-Rearranged Lung Adenocarcinoma? Journal of Clinical Oncology. 33: 3681-3683. PMID 26417000 DOI: 10.1200/Jco.2015.63.2976  0.382
2015 Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth SJ, Buller R, Walker I, Carr TH, Wherton D, Billingham LJ. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26410619 DOI: 10.1093/Annonc/Mdv394  0.407
2015 Turajlic S, Swanton C. Gastrointestinal cancer: Tracking tumour evolution through liquid biopsy Nature Reviews Clinical Oncology. 12: 565-566. PMID 26346844 DOI: 10.1038/Nrclinonc.2015.153  0.419
2015 Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, Caldas C, Califano A, Doherty M, Elsner M, Esteller M, Fitzgerald R, Korbel JO, Lichter P, Mason CE, ... ... Swanton C, et al. Toward understanding and exploiting tumor heterogeneity. Nature Medicine. 21: 846-53. PMID 26248267 DOI: 10.1038/Nm.3915  0.311
2015 Turajlic S, Larkin J, Swanton C. Academically led clinical trials: challenges and opportunities. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 2010-1. PMID 26240217 DOI: 10.1093/Annonc/Mdv332  0.423
2015 Soultati A, Stares M, Swanton C, Larkin J, Turajlic S. How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma? Current Opinion in Urology. 25: 358-66. PMID 26125509 DOI: 10.1097/Mou.0000000000000204  0.362
2015 Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discovery. 5: 704-12. PMID 26091828 DOI: 10.1158/2159-8290.Cd-15-0344  0.409
2015 Murugaesu N, Wilson GA, Birkbak NJ, Watkins TB, McGranahan N, Kumar S, Abbassi-Ghadi N, Salm M, Mitter R, Horswell S, Rowan A, Phillimore B, Biggs J, Begum S, Matthews N, ... ... Swanton C, et al. Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy. Cancer Discovery. PMID 26003801 DOI: 10.1158/2159-8290.Cd-15-0412  0.372
2015 Jamal-Hanjani M, A'Hern R, Birkbak NJ, Gorman P, Grönroos E, Ngang S, Nicola P, Rahman L, Thanopoulou E, Kelly G, Ellis P, Barrett-Lee P, Johnston SR, Bliss J, Roylance R, ... Swanton C, et al. Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1340-6. PMID 26003169 DOI: 10.1093/Annonc/Mdv178  0.435
2015 Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity Nature Reviews Clinical Oncology. 12: 381-394. PMID 25895611 DOI: 10.1038/Nrclinonc.2015.73  0.395
2015 McGranahan N, Favero F, Bruin ECd, Birkbak NJ, Szallasi ZI, Swanton C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution Science Translational Medicine. 7. PMID 25877892 DOI: 10.1126/Scitranslmed.Aaa1408  0.399
2015 Leo AD, Curigliano G, Diéras V, Malorni L, Sotiriou C, Swanton C, Thompson A, Tutt A, Piccart M. New approaches for improving outcomes in breast cancer in Europe The Breast. 24: 321-330. PMID 25840656 DOI: 10.1016/J.Breast.2015.03.001  0.413
2015 Turajlic S, McGranahan N, Swanton C. Inferring mutational timing and reconstructing tumour evolutionary histories. Biochimica Et Biophysica Acta. 1855: 264-275. PMID 25827356 DOI: 10.1016/J.Bbcan.2015.03.005  0.393
2015 Kovac M, Navas C, Horswell S, Salm M, Bardella C, Rowan A, Stares M, Castro-Giner F, Fisher R, de Bruin EC, Kovacova M, Gorman M, Makino S, Williams J, Jaeger E, ... ... Swanton C, et al. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nature Communications. 6: 6336. PMID 25790038 DOI: 10.1038/Ncomms7336  0.4
2015 Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implications of tumor heterogeneity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1258-66. PMID 25770293 DOI: 10.1158/1078-0432.Ccr-14-1429  0.451
2015 Favero F, McGranahan N, Salm M, Birkbak NJ, Sanborn JZ, Benz SC, Becq J, Peden JF, Kingsbury Z, Grocok RJ, Humphray S, Bentley D, Spencer-Dene B, Gutteridge A, Brada M, ... ... Swanton C, et al. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 880-7. PMID 25732040 DOI: 10.1093/Annonc/Mdv127  0.384
2015 Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M, Rowan AJ, Patel H, Rabinowitz A, East P, Wilson G, Santos CR, McGranahan N, ... ... Swanton C, et al. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene. PMID 25728682 DOI: 10.1038/Onc.2015.24  0.342
2015 Walther V, Hiley CT, Shibata D, Swanton C, Turner PE, Maley CC. Can oncology recapitulate paleontology? Lessons from species extinctions. Nature Reviews. Clinical Oncology. 12: 273-85. PMID 25687908 DOI: 10.1038/Nrclinonc.2015.12  0.394
2015 Swanton C. Cancer evolution constrained by mutation order. The New England Journal of Medicine. 372: 661-663. PMID 25671259 DOI: 10.1056/Nejme1414288  0.368
2015 McGranahan N, Swanton C. Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution Cancer Cell. 27: 15-26. PMID 25584892 DOI: 10.1016/J.Ccell.2014.12.001  0.459
2015 Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC, Swanton C. Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. European Urology. 67: 729-37. PMID 24836153 DOI: 10.1016/J.Eururo.2014.04.014  0.408
2015 Burris HA, Hurwitz H, Perez EA, Spigel D, Swanton C, Hainsworth JD, Leon L, Beattie M, Brammer M, Sweeney C. MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps11111  0.398
2015 Loi S, Savas P, Lonnstedt I, Fumagalli D, Caramia F, Li J, Salgado R, Rowan A, Andre F, Denkert C, Neven P, Loibl S, Sotiriou C, Swanton C, Speed TP. Abstract PD3-1: Evaluation and clinical impact of intra-tumor heterogeneity (ITH) in primary HER2-overexpressing breast cancers (HER2+BC) treated with adjuvant trastuzumab and chemotherapy (CT) Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd3-1  0.413
2015 Jamal-Hanjani M, Bruin ED, Wilson G, McGranahan N, Rowan A, Mosko M, Metzler H, Nygren A, Swanton C. Abstract 5249: Intratumor heterogeneity and the detection of potential driver mutations in cfDNA in a NSCLC cohort using UltraSEEKTM Cancer Research. 75: 5249-5249. DOI: 10.1158/1538-7445.Am2015-5249  0.411
2014 Swanton C, Beck S. Epigenetic noise fuels cancer evolution. Cancer Cell. 26: 775-6. PMID 25490439 DOI: 10.1016/J.Ccell.2014.11.003  0.429
2014 Hiley CT, Swanton C. Spatial and temporal cancer evolution: causes and consequences of tumour diversity Clinical Medicine. 14. PMID 25468916 DOI: 10.7861/Clinmedicine.14-6-S33  0.419
2014 Andre F, Mardis E, Salm M, Soria JC, Siu LL, Swanton C. Prioritizing targets for precision cancer medicine Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2295-2303. PMID 25344359 DOI: 10.1093/Annonc/Mdu478  0.419
2014 de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan AJ, Grönroos E, Muhammad MA, Horswell S, Gerlinger M, Varela I, ... ... Swanton C, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (New York, N.Y.). 346: 251-6. PMID 25301630 DOI: 10.1126/Science.1253462  0.389
2014 Gerlinger M, McGranahan N, Dewhurst SM, Burrell RA, Tomlinson I, Swanton C. Cancer: evolution within a lifetime. Annual Review of Genetics. 48: 215-36. PMID 25292359 DOI: 10.1146/Annurev-Genet-120213-092314  0.44
2014 Roylance R, Endesfelder D, Jamal-Hanjani M, Burrell RA, Gorman P, Sander J, Murphy N, Birkbak NJ, Hanby AM, Speirs V, Johnston SR, Kschischo M, Swanton C. Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer. Breast Cancer Research and Treatment. 148: 221-9. PMID 25288231 DOI: 10.1007/S10549-014-3153-X  0.401
2014 Lönnstedt IM, Caramia F, Li J, Fumagalli D, Salgado R, Rowan A, Salm M, Kanu N, Savas P, Horswell S, Gade S, Loibl S, Neven P, Sotiriou C, Swanton C, et al. Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data. Genome Biology. 15: 470. PMID 25270265 DOI: 10.1186/S13059-014-0470-7  0.366
2014 Molnár J, Póti Á, Pipek O, Krzystanek M, Kanu N, Swanton C, Tusnády GE, Szallasi Z, Csabai I, Szüts D. The genome of the chicken DT40 bursal lymphoma cell line. G3 (Bethesda, Md.). 4: 2231-40. PMID 25227228 DOI: 10.1534/G3.114.013482  0.339
2014 Hiley C, Bruin ECd, McGranahan N, Swanton C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine Genome Biology. 15: 453-453. PMID 25222836 DOI: 10.1186/S13059-014-0453-8  0.334
2014 Fisher R, Horswell S, Rowan A, Salm MP, de Bruin EC, Gulati S, McGranahan N, Stares M, Gerlinger M, Varela I, Crockford A, Favero F, Quidville V, André F, Navas C, ... ... Swanton C, et al. Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biology. 15: 433. PMID 25159823 DOI: 10.1186/S13059-014-0433-Z  0.359
2014 Stewart GD, Harrison DJ, Swanton C, Lewis R, Bliss J, Larkin J, Nicol DL. Multidisciplinary urological engagement in translational renal cancer research. Bju International. 114: 474-5. PMID 25146641 DOI: 10.1111/Bju.12697  0.323
2014 Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Molecular Oncology. 8: 1095-1111. PMID 25087573 DOI: 10.1016/J.Molonc.2014.06.005  0.363
2014 Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, ... ... Swanton C, et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. Plos Biology. 12: e1001906. PMID 25003521 DOI: 10.1371/Journal.Pbio.1001906  0.445
2014 Bakhoum SF, Swanton C. Chromosomal instability, aneuploidy, and cancer. Frontiers in Oncology. 4: 161. PMID 24995162 DOI: 10.3389/Fonc.2014.00161  0.407
2014 Endesfelder D, Burrell RA, Kanu N, McGranahan N, Howell M, Parker PJ, Downward J, Swanton C, Kschischo M. Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer. Cancer Research. 74: 4853-63. PMID 24970479 DOI: 10.1158/0008-5472.Can-13-2664  0.448
2014 Ng CK, Weigelt B, A'Hern R, Bidard FC, Lemetre C, Swanton C, Shen R, Reis-Filho JS. Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance. Cancer Research. 74: 2946-61. PMID 24706696 DOI: 10.1158/0008-5472.Can-13-3375  0.34
2014 Burrell RA, Swanton C. The evolution of the unstable cancer genome. Current Opinion in Genetics & Development. 24: 61-67. PMID 24657538 DOI: 10.1016/J.Gde.2013.11.011  0.414
2014 Swanton C. Cancer evolution: the final frontier of precision medicine? Annals of Oncology. 25: 549-551. PMID 24567514 DOI: 10.1093/Annonc/Mdu005  0.404
2014 Burrell RA, McClelland SE, Bartek J, Swanton C. Response to Bakhoum et al. Current Biology : Cb. 24: R150. PMID 24556434 DOI: 10.1016/J.Cub.2014.01.021  0.681
2014 Swanton C. SAFIR01: steps towards precision treatment in breast cancer Lancet Oncology. 15: 242-243. PMID 24508106 DOI: 10.1016/S1470-2045(14)70003-8  0.357
2014 Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, Martinez P, Phillimore B, Begum S, Rabinowitz A, Spencer-Dene B, ... ... Swanton C, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nature Genetics. 46: 225-33. PMID 24487277 DOI: 10.1038/Ng.2891  0.35
2014 Dewhurst SM, McGranahan N, Burrell RA, Rowan AJ, Grönroos E, Endesfelder D, Joshi T, Mouradov D, Gibbs P, Ward RL, Hawkins NJ, Szallasi Z, Sieber OM, Swanton C. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discovery. 4: 175-85. PMID 24436049 DOI: 10.1158/2159-8290.Cd-13-0285  0.416
2014 Crockford A, Jamal-Hanjani M, Hicks J, Swanton C. Implications of intratumour heterogeneity for treatment stratification. The Journal of Pathology. 232: 264-73. PMID 24115146 DOI: 10.1002/Path.4270  0.358
2014 Fisher RA, Rowan A, Stares M, Webster-Smith MF, Lewis R, Kilburn LS, Nicol D, Stewart G, Michael A, Vasudev N, Hazell S, Turaljic S, Pickering LM, Gore ME, Snowdon C, ... ... Swanton C, et al. A-PREDICT: A phase II study of axitinib in patients with metastatic renal cell cancer unsuitable for nephrectomy (CRUKE/11/061). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps4597  0.347
2014 Bruin ED, McGranahan N, Yates L, Jamal-Hanjani M, Salm M, Mitter R, Shafi S, Murugaesu N, Rowan A, Gerlinger M, Wedge D, Horswell S, Varela I, Tom W, Parikh C, ... ... Swanton C, et al. Abstract 983: Intratumor heterogeneity in non-small cell lung cancer inferred by multi-region exome sequencing Cancer Research. 74: 983-983. DOI: 10.1158/1538-7445.Am2014-983  0.449
2014 Flechsig S, Wulf-Goldenberg A, Schmees C, Jandrig B, Hennenlotter J, Bedke J, Schostak M, Crockford A, Gerlinger M, Larkin J, Swanton C, Szallasi Z, Fichtner I, Hoffmann J. Abstract 1192: Establishment and characterization of a new patient-derived renal cell carcinoma xenograft panel Cancer Research. 74: 1192-1192. DOI: 10.1158/1538-7445.Am2014-1192  0.387
2014 Jamal-Hanjani M, Wilson G, Bruin ED, McGranahan N, Mitter R, Salm M, Wedge D, Rowan A, Campbell P, Swanton C. Lba36Evolution Of The Genomic Landscape In Non-Small Cell Lung Cancer Annals of Oncology. 25. DOI: 10.1093/Annonc/Mdu438.44  0.45
2014 Swanton C. 104Inintrapatient Heterogeneity And Clonal Evolution: What Precision Medicine? Annals of Oncology. 25. DOI: 10.1093/Annonc/Mdu313.3  0.394
2014 Bruin ED, McGranahan N, Salm M, Wedge D, Mitter R, Yates L, Matthews N, Stewart A, Campbell P, Swanton C. 10: Intra-tumour heterogeneity in early-stage lung cancer inferred by multi-region sequencing European Journal of Cancer. 50. DOI: 10.1016/S0959-8049(14)50010-X  0.353
2013 Martinez P, McGranahan N, Birkbak NJ, Gerlinger M, Swanton C. Computational optimisation of targeted DNA sequencing for cancer detection. Scientific Reports. 3: 3309. PMID 24296834 DOI: 10.1038/Srep03309  0.406
2013 de Bruin EC, Taylor TB, Swanton C. Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. Genome Medicine. 5: 101. PMID 24267946 DOI: 10.1186/Gm505  0.334
2013 Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, et al. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Research : Bcr. 15: R110. PMID 24252402 DOI: 10.1186/Bcr3577  0.334
2013 Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, Shende VH, McGranahan N, Rowan AJ, Hazell S, Hamm D, Robins HS, Pickering L, Gore M, Nicol DL, ... ... Swanton C, et al. Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. The Journal of Pathology. 231: 424-32. PMID 24122851 DOI: 10.1002/Path.4284  0.331
2013 Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 501: 338-345. PMID 24048066 DOI: 10.1038/Nature12625  0.429
2013 Moorcraft SY, Chau I, Peckitt C, Cunningham D, Rao S, Yim KL, Walther A, Jackson CG, Stamp G, Webb J, Smith G, Gillbanks A, Swanton C. Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. Investigational New Drugs. 31: 1339-44. PMID 23801302 DOI: 10.1007/S10637-013-9990-3  0.371
2013 Martinez P, Birkbak NJ, Gerlinger M, McGranahan N, Burrell RA, Rowan AJ, Joshi T, Fisher R, Larkin J, Szallasi Z, Swanton C. Parallel evolution of tumour subclones mimics diversity between tumours. The Journal of Pathology. 230: 356-64. PMID 23716380 DOI: 10.1002/Path.4214  0.336
2013 Munoz J, Swanton C, Kurzrock R. Molecular profiling and the reclassification of cancer: divide and conquer. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 127-34. PMID 23714478 DOI: 10.1200/EdBook_AM.2013.33.127  0.36
2013 Murugaesu N, Chew SK, Swanton C. Adapting clinical paradigms to the challenges of cancer clonal evolution. The American Journal of Pathology. 182: 1962-71. PMID 23708210 DOI: 10.1016/J.Ajpath.2013.02.026  0.444
2013 Jamal-Hanjani M, Thanopoulou E, Peggs KS, Quezada SA, Swanton C. Tumour heterogeneity and immune-modulation. Current Opinion in Pharmacology. 13: 497-503. PMID 23664091 DOI: 10.1016/J.Coph.2013.04.006  0.405
2013 A'Hern RP, Jamal-Hanjani M, Szász AM, Johnston SR, Reis-Filho JS, Roylance R, Swanton C. Taxane benefit in breast cancer--a role for grade and chromosomal stability. Nature Reviews. Clinical Oncology. 10: 357-64. PMID 23648828 DOI: 10.1038/Nrclinonc.2013.67  0.407
2013 Szász AM, Ács B, Ágoston E, Sztupinszki Z, Tőkés AM, Szittya L, Székely B, Szendrői M, Li Q, Harsányi L, Tímár J, Szállási Z, Swanton C, Győrffy B, Kulka J. [Simplified, low-cost gene expression profiling for the prediction of outcome in breast cancer based on routine histologic specimens]. Orvosi Hetilap. 154: 627-32. PMID 23587542 DOI: 10.1556/Oh.2013.29590  0.321
2013 Szekely B, Iwamoto T, Szasz AM, Qi Y, Matsuoka J, Symmans WF, Tokes AM, Kulka J, Swanton C, Pusztai L. A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories. Breast Cancer Research and Treatment. 138: 691-8. PMID 23504136 DOI: 10.1007/S10549-013-2475-4  0.388
2013 Szász AM, Li Q, Eklund AC, Sztupinszki Z, Rowan A, TÅ‘kés AM, Székely B, Kiss A, SzendrÅ‘i M, GyÅ‘rffy B, Szállási Z, Swanton C, Kulka J. The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer. Plos One. 8: e56707. PMID 23468873 DOI: 10.1371/Journal.Pone.0056707  0.405
2013 Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller MC, Shaikh N, Domingo E, Kanu N, Dewhurst SM, Gronroos E, Chew SK, Rowan AJ, Schenk A, Sheffer M, Howell M, ... ... Swanton C, et al. Replication stress links structural and numerical cancer chromosomal instability. Nature. 494: 492-6. PMID 23446422 DOI: 10.1038/Nature11935  0.709
2013 S Datta R, Gutteridge A, Swanton C, Maley CC, Graham TA. Modelling the evolution of genetic instability during tumour progression. Evolutionary Applications. 6: 20-33. PMID 23396531 DOI: 10.1111/Eva.12024  0.302
2013 Azim HA, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M, Neven P, Symmans WF, Thompson A, André F, Loi S, Swanton C. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement Annals of Oncology. 24: 647-654. PMID 23337633 DOI: 10.1093/Annonc/Mds645  0.358
2013 Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. British Journal of Cancer. 108: 479-85. PMID 23299535 DOI: 10.1038/Bjc.2012.581  0.41
2013 Khattak MA, Bakr F, Krzystanek M, Szallasi Z, Gerlinger M, Santos C, Swanton C, Pickering LM, Gore ME, Larkin JM. Prognostic and predictive markers in metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 971-2. PMID 23295806 DOI: 10.1200/Jco.2012.46.9353  0.334
2013 Lu L, Teixeira VH, Yuan Z, Graham TA, Endesfelder D, Kolluri K, Al-Juffali N, Hamilton N, Nicholson AG, Falzon M, Kschischo M, Swanton C, Wright NA, Carroll B, Watt FM, et al. LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development. The Journal of Pathology. 229: 608-20. PMID 23208928 DOI: 10.1002/Path.4148  0.351
2013 Horswell S, Matthews N, Swanton C. Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challenges. Cancer Letters. 340: 220-6. PMID 23142290 DOI: 10.1016/J.Canlet.2012.10.031  0.362
2013 Swanton C. Plasma-Derived Tumor DNA Analysis at Whole-Genome Resolution Clinical Chemistry. 59: 6-8. PMID 23115052 DOI: 10.1373/Clinchem.2012.197053  0.42
2013 Swanton C. Abstract IA15: Genetic and functional tumor heterogeneity Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-Ia15  0.417
2013 Gerlinger M, Horswell S, Larkin J, Rowan AJ, Martinez P, Varela I, Santos CR, Fisher R, Salm MP, Szallasi Z, Matthews N, Stewart A, Futreal PA, Swanton C. Abstract 4603: Intratumor heterogeneity in clear cell renal cell carcinoma (ccRCC): Multi-region sequencing redefines the mutational landscape of ccRCCs. Cancer Research. 73: 4603-4603. DOI: 10.1158/1538-7445.Am2013-4603  0.407
2013 Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller M, Shaikh N, Domingo E, Kanu N, Dewhurst SM, Gronroos E, Chew SK, Rowan AJ, Schenk A, Sheffer M, Howell M, ... ... Swanton C, et al. Corrigendum: Replication stress links structural and numerical cancer chromosomal instability Nature. 500: 490-490. DOI: 10.1038/Nature12369  0.704
2012 Hewish M, Stamp G, Puckey L, Shanley S, Costello C, Webb J, Hulkki Wilson S, Gonzalez de Castro D, Barbachano Y, Saffery C, Swanton C, Lord CJ, Reis-Filho JS, Ashworth A, Chau I, et al. Impact of mismatch repair (MMR) testing on colorectal cancer (CRC) oncology clinical practice. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 603. PMID 27983414 DOI: 10.1200/Jco.2012.30.4_Suppl.603  0.331
2012 Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Research. 72: 4875-4882. PMID 23002210 DOI: 10.1158/0008-5472.Can-12-2217  0.379
2012 Weigelt B, Reis-Filho JS, Swanton C. Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations Annals of Oncology. 23. PMID 22987965 DOI: 10.1093/Annonc/Mds323  0.424
2012 Staples CJ, Myers KN, Beveridge RD, Patil AA, Lee AJ, Swanton C, Howell M, Boulton SJ, Collis SJ. The centriolar satellite protein Cep131 is important for genome stability. Journal of Cell Science. 125: 4770-9. PMID 22797915 DOI: 10.1242/Jcs.104059  0.316
2012 Fennell DA, Swanton C. Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer. The Epma Journal. 3: 6. PMID 22738201 DOI: 10.1186/1878-5085-3-6  0.411
2012 Yap TA, Swanton C, Bono JSd. Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? The Epma Journal. 3: 3-3. PMID 22738151 DOI: 10.1007/S13167-011-0138-2  0.36
2012 McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C. Cancer chromosomal instability: therapeutic and diagnostic challenges. Embo Reports. 13: 528-538. PMID 22595889 DOI: 10.1038/Embor.2012.61  0.416
2012 Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor Heterogeneity: Seeing the Wood for the Trees Science Translational Medicine. 4. PMID 22461637 DOI: 10.1126/Scitranslmed.3003854  0.342
2012 Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, ... ... Swanton C, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine. 366: 883-92. PMID 22397650 DOI: 10.1056/Nejmoa1113205  0.349
2012 Gerlinger M, Santos CR, Spencer-Dene B, Martinez P, Endesfelder D, Burrell RA, Vetter M, Jiang M, Saunders RE, Kelly G, Dykema K, Rioux-Leclercq N, Stamp G, Patard JJ, Larkin J, ... ... Swanton C, et al. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. The Journal of Pathology. 227: 146-56. PMID 22362593 DOI: 10.1002/Path.4006  0.332
2012 Natrajan R, Mackay A, Lambros MB, Weigelt B, Wilkerson PM, Manie E, Grigoriadis A, A'hern R, van der Groep P, Kozarewa I, Popova T, Mariani O, Turajlic S, Furney SJ, Marais R, ... ... Swanton C, et al. A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. The Journal of Pathology. 227: 29-41. PMID 22362584 DOI: 10.1002/Path.4003  0.399
2012 Lee AJX, Swanton C. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics. Biochemical Pharmacology. 83: 1013-1020. PMID 22192819 DOI: 10.1016/J.Bcp.2011.12.008  0.383
2012 Lee AJ, Roylance R, Sander J, Gorman P, Endesfelder D, Kschischo M, Jones NP, East P, Nicke B, Spassieva S, Obeid LM, Birkbak NJ, Szallasi Z, McKnight NC, Rowan AJ, ... ... Swanton C, et al. CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. The Journal of Pathology. 226: 482-94. PMID 21953249 DOI: 10.1002/Path.2998  0.442
2012 Swanton C, Cromer J. Open-label, phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps650  0.381
2012 Swanton C, Sutherland S, Cromer J, Kaci MO. Abstract LB-453: Phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC). A biomarker driven study using ultra deep genome sequencing technology Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-453  0.423
2012 Gerlinger M, Rowan A, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald N, Butler A, ... ... Swanton C, et al. Abstract 964: Intra-tumor heterogeneity and Darwinian selection revealed by multi-region exome sequencing of renal cell carcinomas Cancer Research. 72: 964-964. DOI: 10.1158/1538-7445.Am2012-964  0.383
2012 Burrell RA, McClelland SE, Endesfelder D, Rowan A, Schenk A, Sheffer M, Shaikh N, Domingo E, Kschischo M, Domany E, Downward J, Tomlinson I, Swanton C. Abstract 3105: Chromosome 18q encodes a chromosomal instability suppressor locus in colorectal cancer Cancer Research. 72: 3105-3105. DOI: 10.1158/1538-7445.Am2012-3105  0.711
2012 A'Hern R, Bliss J, Szallasi Z, Johnston S, Roylance R, Swanton C. Abstract P6-07-15: The effect of taxanes in ER+ early breast cancer is likely to be mitigated by chromosomal instability. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-07-15  0.445
2012 Swanton C. My Cancer Genome: a unified genomics and clinical trial portal Lancet Oncology. 13: 668-669. DOI: 10.1016/S1470-2045(12)70312-1  0.353
2012 Szasz A, Geszti F, Zsákovics I, Székely B, Tokes AM, Rowan A, Swanton C, Krenács T, Kulka J. 344 Cell-cycle Phase Specific Markers’ Expression in Breast Cancer European Journal of Cancer. 48. DOI: 10.1016/S0959-8049(12)70410-0  0.361
2011 Han HS, Swanton C, Janjigian YY, Sutherland SC, Chandarlapaty S, Lehman R, Hamilton N, Knowles J, Lee R, Yan L, Sullivan D, Hudis C. A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3028. PMID 28022686 DOI: 10.1200/Jco.2011.29.15_Suppl.3028  0.324
2011 Basu B, Ang JE, Crawley D, Folkerd E, Sarker D, Blanco-Codesido M, Moran K, Wan S, Dobbs N, Raynaud F, Johnston SR, Dowsett M, Tutt AN, Spicer JF, Swanton C, et al. Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor- (ER) or androgen receptor (AR) -positive advanced breast carcinoma resistant to standard endocrine therapies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2525. PMID 28022340 DOI: 10.1200/Jco.2011.29.15_Suppl.2525  0.326
2011 Fisher R, Larkin J, Swanton C. Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. The Epma Journal. 3: 1. PMID 22738081 DOI: 10.1007/S13167-011-0137-3  0.344
2011 Barton S, Swanton C. Recent developments in treatment stratification for metastatic breast cancer. Drugs. 71: 2099-2113. PMID 22035512 DOI: 10.2165/11594480-000000000-00000  0.403
2011 Wong H, Leung R, Kwong A, Chiu J, Liang R, Swanton C, Yau T. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer. The Oncologist. 16: 1535-46. PMID 22020213 DOI: 10.1634/Theoncologist.2011-0165  0.408
2011 Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Kschischo M, Szallasi Z, Swanton C. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 2183-94. PMID 21784954 DOI: 10.1158/1055-9965.Epi-11-0343  0.43
2011 Endesfelder D, McGranahan N, Birkbak NJ, Szallasi Z, Kschischo M, Graham TA, Swanton C. A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables. Oncotarget. 2: 529-37. PMID 21709316 DOI: 10.18632/Oncotarget.298  0.412
2011 Larkin J, Swanton C, Pickering L. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Review of Anticancer Therapy. 11: 639-49. PMID 21504330 DOI: 10.1586/Era.11.21  0.304
2011 Kumar MS, Swanton C. KRAS 3′-UTR variants and stratification of breast-cancer risk Lancet Oncology. 12: 318-319. PMID 21435949 DOI: 10.1016/S1470-2045(11)70065-1  0.347
2011 Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M, Kschischo M, Swanton C. Chromosomal instability confers intrinsic multidrug resistance. Cancer Research. 71: 1858-70. PMID 21363922 DOI: 10.1158/0008-5472.Can-10-3604  0.435
2011 Swanton C, Burrell RA, Futreal PA. Breast cancer genome heterogeneity: a challenge to personalised medicine? Breast Cancer Research. 13: 104-104. PMID 21345264 DOI: 10.1186/Bcr2807  0.412
2011 Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z, Swanton C. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Research. 71: 3447-52. PMID 21270108 DOI: 10.1158/0008-5472.Can-10-3667  0.75
2011 Krzystanek M, Eklund AC, Birkbak NJ, Tegze B, Gautier L, Blicher LH, Swanton C, Richardson AL, Gyorffy B, Szallasi ZI. Parallel selection of chemotherapy-resistant cell lines to illuminate mechanisms of drug resistance in human tumors: Abstract of paper from the IMPAKT Breast Cancer Conference Annals of Oncology. 22. DOI: 10.1093/Annonc/Mdr086  0.367
2011 Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Erratum: Genetic prognostic and predictive markers in colorectal cancer Nature Reviews Cancer. 11: 309-309. DOI: 10.1038/Nrc3042  0.37
2011 Szasz A, Li Q, Sztupinszki Z, Tokes AM, Szekely B, Szendroi M, Gyorffy B, Szallasi Z, Swanton C, Kulka J. 1437 POSTER Gene Expression Signature TOPFOX Reflecting Chromosomal Instability Refines Prediction of Prognosis in Grade 2 Breast Cancer European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)70930-3  0.394
2010 Li Q, Eklund AC, Juul N, Haibe-Kains B, Workman CT, Richardson AL, Szallasi Z, Swanton C. Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status. Plos One. 5: e15031. PMID 21152022 DOI: 10.1371/Journal.Pone.0015031  0.33
2010 Swanton C, Caldas C. From genomic landscapes to personalized cancer management-is there a roadmap? Annals of the New York Academy of Sciences. 1210: 34-44. PMID 20973797 DOI: 10.1111/J.1749-6632.2010.05776.X  0.36
2010 Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. British Journal of Cancer. 103: 1139-1143. PMID 20877357 DOI: 10.1038/Sj.Bjc.6605912  0.413
2010 Barton S, Starling N, Swanton C. Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies. Current Cancer Drug Targets. 10: 799-812. PMID 20718710 DOI: 10.2174/156800910793357925  0.372
2010 Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, Downward J, Gore M, Futreal PA, Escudier B, Andre F, Albiges L, Beuselinck B, Oudard S, Hoffmann J, et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Medicine. 2: 53. PMID 20701793 DOI: 10.1186/Gm174  0.379
2010 Burrell RA, Juul N, Johnston SR, Reis-Filho JS, Szallasi Z, Swanton C. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer Journal of Cellular Biochemistry. 111: 782-790. PMID 20665662 DOI: 10.1002/Jcb.22781  0.433
2010 Brunetto AT, Sarker D, Papadatos-Pastos D, Fehrmann R, Kaye SB, Johnston S, Allen M, Bono JSD, Swanton C. A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. British Journal of Cancer. 103: 607-612. PMID 20664586 DOI: 10.1038/Sj.Bjc.6605812  0.349
2010 Tan DS, Gerlinger M, Teh BT, Swanton C. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. European Journal of Cancer (Oxford, England : 1990). 46: 2166-77. PMID 20413300 DOI: 10.1016/J.Ejca.2010.03.019  0.364
2010 Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, ... Swanton C, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. The Oncologist. 15: 390-404. PMID 20350999 DOI: 10.1634/Theoncologist.2009-0233  0.422
2010 Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials Lancet Oncology. 11: 358-365. PMID 20189874 DOI: 10.1016/S1470-2045(10)70018-8  0.424
2010 McKeen HD, Byrne C, Jithesh PV, Donley C, Valentine A, Yakkundi A, O'Rourke M, Swanton C, McCarthy HO, Hirst DG, Robson T. FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy. Cancer Research. 70: 1090-100. PMID 20103631 DOI: 10.1158/0008-5472.Can-09-2515  0.401
2010 Swanton C, Juul N, Larkin J, Eklund AC, Li Q, Desmedt C, Sotiriou C, Pusztai L, Szallasi Z. Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer. Journal of Clinical Oncology. 28: 569-569. DOI: 10.1200/Jco.2010.28.15_Suppl.569  0.419
2010 Johnston SR, Swanton C, Stein SH, Liu Y, Gagnon RC, Trudeau ME, Kaufman B, Martin A, Salazar VM. Biomarker profiles and changes from baseline in trastuzumab (T) refractory HER2-positive inflammatory breast cancer (IBC) that predict decreases in tumor burden from lapatinib (L) monotherapy. Journal of Clinical Oncology. 28: 10572-10572. DOI: 10.1200/Jco.2010.28.15_Suppl.10572  0.334
2010 Swanton C. Breast cancer in the post-genomic era British Journal of Cancer. 103: 155-155. DOI: 10.1038/Sj.Bjc.6605681  0.428
2010 Szasz A, Tokes AM, Szittya L, Baranyak ZS, Szekely B, Eklund A, Li Q, Swanton C, Szallasi Z, Kulka J. 571 A focused, PCR based gene expression signature to refine grade in breast cancer Ejc Supplements. 8: 226. DOI: 10.1016/S1359-6349(10)70592-9  0.354
2009 Larkin JM, Kipps EL, Powell CJ, Swanton C. Systemic therapy for advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology. 1: 15-27. PMID 21789110 DOI: 10.1177/1758834009338430  0.326
2009 Burrell RA, Swanton C. Advances in personalised therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivity Cancer Biology & Therapy. 8: 2051-2053. PMID 19816149 DOI: 10.4161/Cbt.8.21.9886  0.347
2009 McClelland SE, Burrell RA, Swanton C. Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy Cell Cycle. 8: 3262-3266. PMID 19806022 DOI: 10.4161/Cc.8.20.9690  0.717
2009 Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nature Reviews Cancer. 9: 489-499. PMID 19536109 DOI: 10.1038/Nrc2645  0.388
2009 Lee AJ, Kolesnick R, Swanton C. RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance. Expert Reviews in Molecular Medicine. 11: e15. PMID 19467173 DOI: 10.1017/S1462399409001070  0.337
2009 Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P, Kschischo M, Endesfelder D, Wylie P, Kim SN, Chen JG, et al. Chromosomal instability determines taxane response. Proceedings of the National Academy of Sciences of the United States of America. 106: 8671-6. PMID 19458043 DOI: 10.1073/Pnas.0811835106  0.432
2009 Swanton C, Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics British Journal of Cancer. 100: 1517-1522. PMID 19367275 DOI: 10.1038/Sj.Bjc.6605031  0.364
2009 Johnston S, Swanton C, Salazar V, Stein S, Liu Y, Gagnon R, Trudeau M, Kaufman B, Martin A. Biomarker Profiles in Trastuzumab (T) Refractory HER2+ Inflammatory Breast Cancer (IBC) That Predict for Survival Benefit from Lapatinib (L) Monotherapy. Cancer Research. 69: 706-706. DOI: 10.1158/0008-5472.Sabcs-09-706  0.315
2009 Swanton C, Juul NS, Li Q, Eklund AC, Richardson A, Szallasi ZI. Paradoxical Relationship of Chromosomal Instability with Breast Cancer Outcome: Identification of a Good Prognostic ER Negative/HER2 Negative Breast Cancer Cohort with Extreme Chromosomal Instability. Cancer Research. 69: 3030-3030. DOI: 10.1158/0008-5472.Sabcs-09-3030  0.44
2009 Burrell RA, McClelland SE, Juul NS, Downward J, Szallasi ZI, Swanton C. Regulators of Mitotic Transition Determine Paclitaxel Resistance In Vitro and Predict Poor Prognosis in Breast Cancer In Vivo. Cancer Research. 69: 2151-2151. DOI: 10.1158/0008-5472.Sabcs-09-2151  0.735
2009 Juul NS, Eklund AC, Li Q, Downward J, Burrell R, Szallasi ZI, Swanton C. A Functional Metagene Incorporating TTK Protein Kinase, Aurora Kinase B and Glucosylceramide Synthase Predicts Response to Treatment in Primary Breast Cancer Cancer Research. 69: 2032-2032. DOI: 10.1158/0008-5472.Sabcs-09-2032  0.374
2009 Lee A, East P, Nicke B, Jones N, Downward J, Gorman P, Roylance R, Murphy N, Hanby A, Swanton C. A Functional Role for CERT in Cancer Drug Induced Autophagy and Prognosis in Her2 Positive Breast Cancer. Cancer Research. 69: 1137-1137. DOI: 10.1158/0008-5472.Sabcs-09-1137  0.428
2009 Juul N, Wang Y, Kim J, Eklund A, Li Q, Carlton V, Gerlinger M, Swanton C, Garber J, Silver D, Faham M, Richardson A, Szallasi Z, Wang Z. A Genomic-Profile Derived Summary Measure of Chromosomal Breakpoints Predicts Response to Treatment with the DNA-Damaging Agent Cisplatin. Cancer Research. 69: 111-111. DOI: 10.1158/0008-5472.Sabcs-09-111  0.307
2008 Lee AJ, East P, Pepper S, Nicke B, Szallasi Z, Eklund AC, Downward J, Swanton C. Concordance of exon array and real-time PCR assessment of gene expression following cancer cell cytotoxic drug exposure. Cell Cycle (Georgetown, Tex.). 7: 3947-8. PMID 19066460 DOI: 10.4161/Cc.7.24.7217  0.336
2008 Swanton C, Szallasi Z, Brenton JD, Downward J. Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. Breast Cancer Research : Bcr. 10: 214. PMID 18986507 DOI: 10.1186/Bcr2159  0.405
2008 Olmos D, Swanton C, Bono Jd. Targeting Polo-Like Kinase: Learning Too Little Too Late? Journal of Clinical Oncology. 26: 5497-5499. PMID 18955441 DOI: 10.1200/Jco.2008.18.6585  0.333
2008 Harrison M, Swanton C. Epothilones and new analogues of the microtubule modulators in taxane-resistant disease. Expert Opinion On Investigational Drugs. 17: 523-546. PMID 18363517 DOI: 10.1517/13543784.17.4.523  0.324
2008 Swanton C, Downward J. Unraveling the complexity of endocrine resistance in breast cancer by functional genomics. Cancer Cell. 13: 83-5. PMID 18242507 DOI: 10.1016/J.Ccr.2008.01.021  0.429
2007 Ahmed AA, Mills AD, Ibrahim AE, Temple J, Blenkiron C, Vias M, Massie CE, Iyer NG, McGeoch A, Crawford R, Nicke B, Downward J, Swanton C, Bell SD, Earl HM, et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 12: 514-27. PMID 18068629 DOI: 10.1016/J.Ccr.2007.11.014  0.354
2007 Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, Elustondo F, Chang J, Temple J, Ahmed AA, Brenton JD, Downward J, Nicke B. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell. 11: 498-512. PMID 17560332 DOI: 10.1016/J.Ccr.2007.04.011  0.414
2006 Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell lung cancer Clinical Cancer Research. 12. PMID 16857814 DOI: 10.1158/1078-0432.Ccr-06-0115  0.363
2006 Swanton C, Tomlinson I, Downward J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle (Georgetown, Tex.). 5: 818-23. PMID 16628000 DOI: 10.4161/Cc.5.8.2682  0.4
2006 Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, Johnston SR, O'Brien ME, Smith IE. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncologica (Stockholm, Sweden). 45: 196-201. PMID 16546866 DOI: 10.1080/02841860500486630  0.332
2004 Swanton C. Cell-cycle targeted therapies Lancet Oncology. 5: 27-36. PMID 14700606 DOI: 10.1016/S1470-2045(03)01321-4  0.311
2000 Cunliffe DR, Swanton C, White C, Watt-Smith SR, Cook TA, George BD. Percutaneous endoscopic gastrostomy at the time of tumour resection in advanced oral cancer. Oral Oncology. 36: 471-3. PMID 10964056 DOI: 10.1016/S1368-8375(00)00038-5  0.311
Show low-probability matches.